Professional
Added to YB: 2025-12-01
Pitch date: 2025-10-31
GSK [neutral]
GSK plc
+3.77%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 73.3B
Pitch Price
GBP 17.67
Price Target
N/A
Dividend
3.34%
EV/EBITDA
8.97
P/E
13.73
EV/Sales
2.71
Sector
Pharmaceuticals
Category
growth
Liontrust Special Situations Fund Portfolio Holding: GSK plc
GSK (holding update): +13% after raising 2025 guidance on strong double-digit growth from specialty HIV & oncology drugs. Revenue forecast raised to 6-7% (vs 3-5% prior), core EPS to 10-12% (vs 6-8% prior). Outperforming on specialty drug portfolio strength.
Read full article (1 min)